Peter,
Pharmacoeconomic means different things to different people, and the following references should cover a useful spectrum Poland B, Wada R. Combining drug-disease and economic modelling to inform drug development decisions Drug Discovery Today. November 2001;6(22):1165-1170. Korsan B, Dykstra K, Pullman W. Transparent Trade-Offs: A Clinical Utility Index (CUI) Openly Evaluates a Product's Attributes - and Chance of Success Pharmaceutical Executive. March 2005. Poland B, Hodge F, Khan A, Clemen R, Dykstra K, Krishna R. The Clinical Utility Index as a Practical Multiattribute Approach to Drug Development Decisions (Accepted 2009) Dykstra K, Hodge F, Carrothers TJ, Korsan B. Linking Modeling & Simulation, Decision Analysis, and the Technology of Drug Formulation American Conference on Pharmacometrics (ACoP); March 9-12, 2008; Tucson, Arizona Hodge F, Using the Clinical Utility Index (CUI) to Inform Dose Selection Decisions; Webinar February 2009; http://www.pharsight.com/events/eventsonline_archive.php#replay_028 Korsan B, Modeling and Decision Analysis to Support Formulation Selection and Trial Sequencing, Webinar April 2006 http://www.pharsight.com/events/eventsonline_archive.php#replay_003 Cheers -Jon ________________________________ From: [email protected] [mailto:[email protected]] On Behalf Of [email protected] Sent: Thursday, April 23, 2009 4:39 PM To: Bonate, Peter; [email protected] Subject: Re: [NMusers] Pharmacoeconomic simulations A clinical utility index (CUI), as described recently by Ouellet et al. Clinical Pharmacology & Therapeutics (2009); 85, 3, 277-282 as well as by others elsewhere, is amenable to being used as a pharmacoeconomic vehicle. Typically the CUI is derived in terms of patient benefit:risk, but could easily be adapted to other tangible measures of value. Jeff "Bonate, Peter" <[email protected]> Sent by: [email protected] 23-Apr-2009 10:37 To [email protected] cc Subject [NMusers] Pharmacoeconomic simulations Is anyone aware of any papers or abstracts using computer-assisted trial design that incorporates a pharmacoeconomic component to the simulation? Or any pop pharmacokinetic-pharmacodynamic papers that include the same? Thanks Pete bonate Peter L. Bonate, PhD, FCP Genzyme Corporation Senior Director Clinical Pharmacology and Pharmacokinetics 4545 Horizon Hill Blvd San Antonio, TX 78229 USA [email protected] <mailto:[email protected]> phone: 210-949-8662 fax: 210-949-8219 crackberry: 210-315-2713 "Beware of geeks bearing formulas". Written by Warren Buffet as part of Berkshire Hathaway's 2009 Annual Report to Stockholders.
<<image001.gif>>
